[markolschesky]

The textbook answer is typically that there is exponentially more data in unstructured data, but I agree with you. I thought about the unmodified use cases for this tooling for awhile and the major use case that I could come up with was finding unknown interactions or side-effects for medication and treatment combination regimens. That's all tracked very poorly in discrete fields today, especially with the nightmare that is cross-organization problem list management. Most drugs are approved by the FDA with the understanding that there will be post-marketing research (read this: https://undark.org/article/fda-drugs-post-marketing-research...), which this could hypothetically streamline.